| Assessment Status | Rapid Review complete |
| HTA ID | 20018 |
| Drug | Benralizumab |
| Brand | Fasenra® |
| Indication | As an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists. |
| Assessment Process | |
| Rapid review commissioned | 31/03/2020 |
| Rapid review completed | 28/04/2020 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that benralizumab not be considered for reimbursement under high tech drug arrangements at the submitted price*. |
* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations October 2021
